A phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of abvd chemotherapy for Hodgkin Lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity

A. Gibb, P. Johnson, A. Greystoke, M. Ranson, K. Linton, C. Dive, S. Neeson, A. Pettit, E. Smith, A. Lister, T. Illidge, J. Radford

Research output: Contribution to journalMeeting Abstractpeer-review

Cite this